FDA Drug recall D-1393-2012
Levothroid (levothyroxine sodium tablets, USP), 50 mcg., packaged in 100-ct. bottles, RX, NDC 0456-1321-01
- FDA Drug
- Class II
- terminated
- Published 2012-07-04
On 2012-07-04 the FDA classified a Class II recall of Levothroid (levothyroxine sodium tablets, USP), 50 mcg., packaged in 100-ct. bottles, RX, NDC 0456-1321-01 by Lloyd, citing subpotent (Single Ingredient Drug): Low assay at the 9-month test interval.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1393-2012 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2012-02-03 |
| Published | 2012-07-04 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Lloyd |
| Distribution | US |
Product
Levothroid (levothyroxine sodium tablets, USP), 50 mcg., packaged in 100-ct. bottles, RX, NDC 0456-1321-01. Manufactured for Forest Pharmaceuticals, Inc., Subsidiary of Forest Laboratories, Inc., St. Louis, MO, by Lloyd Pharmaceutical, Shenandoah, IA.
Reason
Subpotent (Single Ingredient Drug): Low assay at the 9-month test interval.
Identifiers
| code_info | Lot 1087589 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1393-2012%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.